More News

Blocking immune cell signals could make brain tumours easier to remove

Jim Cornall -
In a new study published in Cancer Cell, researchers at VIB-KU Leuven in Belgium reduced the spread of glioblastoma...

Exogenus Therapeutics leads €13m consortium to advance new secretome-based therapy for osteoarthritis

Jim Cornall -
The ExoCordOA consortium has launched a five-year, €13m project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies...

Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

Jim Cornall -
This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart,...

Early results from “encouraging” pancreatic cancer study

Jim Cornall -
ImPact Biotech has announced the successful completion of treatment in part A of its phase 1 clinical trial in...

Familiar Therapeutics launches to close gap between human and veterinary medicine

Jim Cornall -
Familiar Therapeutics has launched with $5m in seed funding to bring the advances of modern human medicine to dogs...

Scientists create white blood cell with memory of how to fight off winter flu bugs

Jim Cornall -
Researchers at the University of Southampton in the UK are developing killer cells, a type of white blood cell,...

Topline results from metastatic breast cancer phase 3 trial

Jim Cornall -
BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. have announced that the DYNASTY-Breast02 global phase 3 clinical trial met its...

Updated prostate cancer results show anti-tumour activity

Jim Cornall -
AdvanCell has announced updated results from the TheraPb phase 1 clinical trial evaluating ADVC001, an investigational lead-212 PSMA-targeted alpha...

Gesynta Pharma continues endometriosis work

Jim Cornall -
Gesynta Pharma AB has completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial. With 213 patients...

First-in-human circular RNA therapy for radiation-induced xerostomia

Jim Cornall -
RiboX Therapeutics has announced the publication of a peer-reviewed Research Letter in The New England Journal of Medicine (NEJM)...

Data show unresectable patients becoming eligible for surgery

Jim Cornall -
Brenus Pharma has announced first data from the phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were...

Personalised cancer vaccine with immunotherapy reduces melanoma recurrence after surgery

Jim Cornall -
Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or...

AI drug choices may cost millions

Jim Cornall -
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the...

Researchers reprogramme pancreatic cancer tumour microenvironment

Jim Cornall -
Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is...

Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

Jim Cornall -
This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also...

New bacteria discovered in DNA samples from prostate cancer patients

admin -
University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer...

Estuary Biotherapeutics launches with $103m to develop gene therapies for kidney disease

Jim Cornall -
Estuary Biotherapeutics, Inc. has launched with $103m in total committed financing. The financing will support advancement of the company’s two...

Data show reduction in skin epigenetic age and systemic inflammatory biomarkers

Jim Cornall -
Rubedo Life Sciences has revealed new phase 1b clinical findings for RLS-1496, its lead investigational GPX4 modulator. In patients with...

Blood proteins may offer clues to gut health in coeliac disease

Jim Cornall -
Coeliac disease is an autoimmune condition in which the immune system reacts adversely to gluten. Eating gluten causes inflammation...

IMU and UK Biobank to generate world’s most detailed picture of the human immune system

Jim Cornall -
IMU Biosciences has announced a collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood...

Positive results from schizophrenia study

Jim Cornall -
Tortugas Neuroscience has announced positive phase 2b trial results for obuprazine (TRTL-107), the company’s investigational treatment for schizophrenia. Results from...